In 2024, ORION achieved revenue of 3.10 trillion KRW (up 6.59% YoY) with earnings of 524.59 billion KRW (up 39.28%). The company operates as a diversified consumer staples player with strong exposure to growing Asian markets, leveraging established brand recognition and vertical integration across multiple food and healthcare segments.
Cyborg Score Rationale
ORION demonstrates solid fundamentals with double-digit earnings growth, stable dividend yield (~1.95-2.44%), and low valuation (PE ratio ~9.35). Recent sales pressure in China reflects macro headwinds rather than structural weakness. The diversified portfolio spanning confectionery, healthcare, and specialty products provides resilience.
Top Insights
Recent January 2026 sales declined 11% in China due to Lunar New Year timing effects, indicating seasonal volatility in key geographic market
Earnings growth significantly outpaced revenue growth (39.28% vs. 6.59% in 2024), suggesting improving operational efficiency and margin expansion
Diversified revenue streams beyond confectionery reduce earnings volatility and provide growth avenues in healthcare diagnostics and vaccines
Trading at attractive valuation with PE ratio of 9.35 and dividend yield of 1.95-2.44%, supported by analyst consensus 'Buy' rating
Named Competitors
Market O — Premium confectionery and snack brand
Dr.You — Protein drinks and nutrition product line
Mondelez International — Global snacking company
Recent Developments
(February 2026) January 2026 China sales declined 11% YoY due to Lunar New Year timing impact
(February 2026) Technical indicators showing 'Strong Buy' rating across daily, weekly, and monthly timeframes
(2024) Earnings increased 39.28% to 524.59 billion KRW with revenue growth of 6.59% to 3.10 trillion KRW
Open the full interactive ORION Corp. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.